Neurizon Therapeutics Limited

NUZ

AU0000357261

Pharmaceuticals

Delayed Australian S.E. Other stock markets 05:12:12 12/12/2025 am IST			5-day change	1st Jan Change
0.1100 ^AUD	-8.33%		+4.76%	-35.29%

11/12	Neurizon Says US FDA Clears Use of Drug Candidate in ALS Clinical Trial	MT
04/12	Neurizon Completes Manufacturing Three Registration Batches of Drug Candidate to Treat Neurodegenerative Disease; Shares Fall 5%	MT

Neurizon Therapeutics Limited(ASX:NUZ) dropped from S&P/ASX Emerging Companies Index

Published on 03/24/2025

S&P Capital IQ

Neurizon Therapeutics Limited

-8.33%

Neurizon Therapeutics Limited(ASX:NUZ) dropped from S&P/ASX Emerging Companies Index

Latest news about Neurizon Therapeutics Limited

11/12	Neurizon Says US FDA Clears Use of Drug Candidate in ALS Clinical Trial	MT
04/12	Neurizon Completes Manufacturing Three Registration Batches of Drug Candidate to Treat Neurodegenerative Disease; Shares Fall 5%	MT
26/11	Neurizon Therapeutics Limited Announces the Appointment of Justine Conway as Board Observer	CI
21/10	Neurizon Therapeutics Secures Australian Patent Covering NUZ-001 Drug Candidate for Neurodegenerative Disease Treatment	MT
06/10	Neurizon Therapeutics Limited Announces U.S. Food and Drug Administration Lifts Clinical Hold on Nuz-001	CI
06/10	FDA lifts clinical hold on Nuz-001	RE
06/10	Neurizon Therapeutics says US FDA lifts clinical hold on NUZ-001	RE
06/10	Neurizon Therapeutics Says US FDA Lifts Clinical Hold on Amyotrophic Lateral Sclerosis Drug Candidate	MT
18/09	Neurizon Therapeutics Secures AU$5 Million Through Share Placement	MT
18/09	Neurizon Therapeutics raises A$5 million at A$0.12 per share	RE
16/09	Neurizon Therapeutics seeks trading halt	RE
26/08	Neurizon Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI
26/08	Neurizon Therapeutics posts loss for year attributable a$16.6 million	RE
20/08	Neurizon Therapeutics Says ALS Drug Candidate Study Confirms Long-Term Treatment at Recommended Dose is Safe, Well-Tolerated	MT
15/08	Neurizon Says US FDA Delays Decision on ALS Drug Application Clinical Hold; Shares Fall 6%	MT
12/08	Neurizon Starts Manufacturing First Registration Batch of Drug Candidate to Treat Neurodegenerative Disease	MT
30/07	Neurizon Therapeutics Secures AU$1.5 Million Loan Against Fiscal Year 2025 R&D Tax Rebate	MT
25/07	Neurizon Therapeutics Submit Formal Response to US FDA for Investigational New Drug Application; Shares Up 19%	MT
10/07	Neurizon Therapeutics Receives US FDA Support to Lift Clinical Hold on ALS Trial	MT
03/07	Elanco Animal Health Enters Into Licensing Agreement With Neurizon for Monepantel	MT
02/07	Neurizon Therapeutics Secures License Deal With Animal Health Company; Shares Up 3%	MT
26/06	Neurizon Therapeutics Develops Oral Liquid Formulation for Amyotrophic Lateral Sclerosis Drug Candidate	MT
20/06	Neurizon Therapeutics Says High Levels of NUZ-001 Drug Candidate Cross Blood-Brain Barrier in Rodent Study	MT
16/06	NUZ-001 Shows Promise In Zebrafish Model Of Huntington's Disease	RE
16/06	Neurizon® Therapeutics Limited Announces New Preclinical Data Demonstrating Significant Neuroprotective Effects of Nuz-001 Sulfone	CI

Chart Neurizon Therapeutics Limited

Duration

Period

NUZ: Dynamic Chart

Neurizon Therapeutics Ltd, formerly PharmAust Limited, is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. The Company is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.

Employees

Sector

Pharmaceuticals

Calendar

26/02 - Q2 2026 Earnings Release (Projected)

More about the company